Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

Despite advancements in melanoma therapy, the prognosis remains unfavorable for many patients. The proteasome inhibitor MG132 has shown therapeutic potential through pathway regulation, yet its ...

Clinical tests of the novel small-molecule inhibitor of p38α MAPK, VX-702, have resulted in an all-too-familiar outcome: modest clinical efficacy and transient inhibition of inflammatory markers.

Induction of MAPK activity was monitored by immunostaining ... To determine whether light elicited CRE-mediated gene expression, CRE-β-galactosidase reporter mice 50 were exposed to light at ...

Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use ofReqorsa® Gene Therapy for the Tre ...